| 5.05 0.3 (6.32%) | 07-10 15:53 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Veradigm Inc. is a global healthcare technology enterprise that delivers cutting-edge information technology platforms to a diverse client base, including healthcare providers, health plans (payers), and biopharmaceutical companies, operating across the United States and various international markets. For healthcare providers, the company offers a suite of integrated solutions designed to optimize operations. These include Practice Management software, AI-driven Patient Scheduling tools, and systems for Electronic Statements and Payments. Veradigm also provides comprehensive revenue cycle management, encompassing specialized services and a dedicated clearinghouse to streamline financial workflows. Furthermore, their electronic health records (EHR) portfolio features advanced options like ePrescribe with EPCS, Veradigm HER, and Practice Fusion HER, complemented by a robust Patient Engagement Platform. The firm extends its offerings to network partners through a variety of connectivity solutions. These comprise API integration tools such as Veradigm Connect and Veradigm App Expo, a Diagnostic Ordering and Resulting Network, a Channel Partner Program, and Veradigm ePrescribe Enterprise. Health plans and payers benefit from Veradigm's specialized solutions, which include sophisticated risk adjustment tools like Health Equity Analytics, Risk Adjustment Analytics, Risk Mitigator, Comprehensive Submissions, and Utilization Analytics. They also provide quality management systems, including quality analytics and integrated risk adjustment and quality management features. Data exchange and coding solutions, such as eChart Courier, eChart Coder, and eChart Integration and Analytics, further enhance efficiency. Additionally, Veradigm offers provider engagement platforms like Veradigm Payer Insights and the comprehensive Veradigm Payerpath suite. For the biopharma sector, Veradigm supplies valuable real-world data solutions, including extensive health datasets and specialized registries for cardiology and metabolic conditions. This is coupled with real-world evidence platforms, such as the Real World Evidence Analytics Platform. Therapy-focused data is available for key areas like cardiovascular, central nervous system, metabolic, and immunology. The company also delivers Digital Health Media solutions. Established in 1986 and headquartered in Chicago, Illinois, Veradigm Inc. was previously known as Allscripts Healthcare Solutions, Inc., before rebranding to its current name in January 2023.
Thu, 09 Jul 2026
Price to sales forward of Veradigm Inc. – OTC:MDRX - TradingView
Tue, 07 Jul 2026
Veradigm Inc updates highlight data-focused healthcare platform - ad-hoc-news.de
Sat, 27 Jun 2026
Veradigm Extends Stockholder Board Observer Agreement Through 2026 - The Globe and Mail
Fri, 26 Jun 2026
Veradigm (MDRX) extends Myers Stockholder Agreement and board observer term through 2026 - Stock Titan
Tue, 26 May 2026
Is Veradigm (MDRX) Undervalued After 10-K Update? FY2024 EPS -$2 - GuruFocus
Tue, 26 May 2026
Veradigm Files 2023 and 2024 Form 10-K - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|